MCID: CTN003
MIFTS: 52

Cutaneous Lupus Erythematosus

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

MalaCards integrated aliases for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 76 53 37 15
Lupus Erythematosus, Cutaneous 53 73
Lupus Erythematosus Cutaneous 55

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169
KEGG 37 H01595
UMLS 73 C0024137

Summaries for Cutaneous Lupus Erythematosus

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to subacute cutaneous lupus erythematosus and lupus erythematosus, and has symptoms including pruritus and exanthema. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Hydroxychloroquine and Ustekinumab have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Subacute Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 subacute cutaneous lupus erythematosus 34.1 CD70 EEA1 TNF TRIM21
2 lupus erythematosus 31.8 TNF TREX1 TRIM21 TROVE2
3 vasculitis 30.2 ICAM1 SELE TNF
4 chilblain lupus 1 30.2 MX1 TREX1 TRIM21
5 rheumatoid arthritis 29.9 ICAM1 IL18 SELE TNF
6 psoriasis 29.9 CXCR3 ICAM1 IL18 SELE TNF
7 lymphadenitis 29.8 CXCR3 ICAM1 IL18 TNF
8 sialadenitis 29.8 TNF TRIM21 TROVE2
9 actinic prurigo 29.7 ICAM1 SELE TNF
10 erythema multiforme 29.5 CXCR3 GZMB ICAM1 TNF
11 lichen planus 29.5 CXCR3 GZMB ICAM1 MX1 TNF
12 alopecia areata 29.4 GZMB ICAM1 TNF
13 systemic lupus erythematosus 29.2 CD70 CXCR3 ICAM1 IL18 MX1 SELE
14 lupus erythematosus tumidus 11.8
15 neonatal lupus erythematosus 11.6
16 dermatomyositis 10.4
17 discoid lupus erythematosus 10.3
18 encephalitozoonosis 10.2 MX1 TNF
19 listeria meningitis 10.2 IL18 TNF
20 alopecia 10.2
21 arthritis 10.2
22 stachybotrys chartarum 10.2 IL18 TNF
23 inflammatory bowel disease 3 10.2 IL18 TNF
24 diffuse infiltrative lymphocytosis syndrome 10.2 TNF TRIM21
25 critical limb ischemia 10.2 SELE TNF
26 scleritis 10.2 SELE TNF
27 porphyria cutanea tarda 10.2
28 porphyria 10.2
29 intermediate uveitis 10.2 CXCR3 TNF
30 retinitis pigmentosa 60 10.2 SELE TNF
31 orofacial granulomatosis 10.2 CXCR3 TNF
32 mycoplasma pneumoniae pneumonia 10.1 IL18 TNF
33 dermatitis 10.1
34 pemphigus 10.1
35 heart block, congenital 10.1 TRIM21 TROVE2
36 mycobacterium tuberculosis 1 10.1 CXCR3 IL18 TNF
37 shwartzman phenomenon 10.1 ICAM1 TNF
38 rheumatic disease 10.1 IL18 TNF TRIM21
39 arthus reaction 10.1 ICAM1 TNF
40 phototoxic dermatitis 10.1 ICAM1 TRIM21
41 pustulosis palmaris et plantaris 10.1 CXCR3 SELE TNF
42 chronic eosinophilic pneumonia 10.1 CXCR3 ICAM1
43 oligoarticular juvenile idiopathic arthritis 10.1 CXCR3 TNF
44 heterophyiasis 10.1 ICAM1 SELE
45 complement component 2 deficiency 10.1
46 hepatitis 10.1
47 panniculitis 10.1
48 herpes zoster 10.1
49 frontal fibrosing alopecia 10.1
50 depression 10.1

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


pruritus, exanthema

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CD70 GZMB ICAM1 IL18 MX1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CD70 GZMB ICAM1 IL18 MX1 TNF

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 CD70 CXCR3 ICAM1 IL18 SELE TNF
2 immune system MP:0005387 9.61 CD70 CXCR3 ICAM1 IL18 SELE TNF
3 integument MP:0010771 9.17 ICAM1 IL18 SELE TNF TREX1 TRIM21

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 3,Phase 2 118-42-3 3652
2
Ustekinumab Approved, Investigational Phase 3 815610-63-0
3 tannic acid Approved Phase 3
4
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
5 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
6 Antiprotozoal Agents Phase 3,Phase 2
7 Antiparasitic Agents Phase 3,Phase 2
8 Antimalarials Phase 3,Phase 2
9 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
10 Dermatologic Agents Phase 3,Phase 2,Not Applicable
11 Radiation-Protective Agents Phase 3,Not Applicable
12 Sunscreening Agents Phase 3,Not Applicable
13 Protective Agents Phase 3,Not Applicable
14
Etanercept Approved, Investigational Phase 2 185243-69-0
15
Norflurane Approved, Experimental Phase 2 811-97-2
16
Tacrolimus Approved, Investigational Phase 2,Not Applicable 104987-11-3 445643 439492
17
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 637568 5271565
18
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
19
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
20
Tofacitinib Approved, Investigational Phase 1, Phase 2,Early Phase 1 477600-75-2
21
Alitretinoin Approved, Investigational Phase 2 5300-03-8 449171 444795
22
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
24
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
25
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
26
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
28 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
29 Immunoglobulins Phase 1, Phase 2,Phase 2,Early Phase 1
30 Antibodies Phase 1, Phase 2,Phase 2,Early Phase 1
31 Anti-Inflammatory Agents Phase 2,Phase 1,Not Applicable
32 Immunologic Factors Phase 2,Early Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 2,Not Applicable
34 Analgesics, Non-Narcotic Phase 2,Phase 1,Not Applicable
35 Analgesics Phase 2,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 2,Phase 1,Not Applicable
37 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1,Not Applicable
38 Gastrointestinal Agents Phase 2
39 Calcineurin Inhibitors Phase 2,Not Applicable
40 Phosphodiesterase 4 Inhibitors Phase 1, Phase 2
41 Phosphodiesterase Inhibitors Phase 1, Phase 2
42 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
43 Anti-Bacterial Agents Phase 2,Not Applicable
44 Angiogenesis Modulating Agents Phase 2,Not Applicable
45 Angiogenesis Inhibitors Phase 2,Not Applicable
46 Vaccines Phase 2
47 Vitamin B Complex Phase 2
48 Vasodilator Agents Phase 2
49 Micronutrients Phase 2
50 Vitamin B9 Phase 2

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
2 Sunscreen RV 2457C in Photoinduced CLE Completed NCT00470912 Phase 3 sunscreen RV 2547C
3 Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Recruiting NCT03178188 Phase 2, Phase 3
4 A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus Recruiting NCT03517722 Phase 3 Placebo;Ustekinumab (approximately 6 mg/kg);Ustekinumab 90 mg
5 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus Recruiting NCT03616964 Phase 3 Baricitinib;Placebo
6 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus Recruiting NCT03616912 Phase 3 Baricitinib;Placebo
7 Phase Ib Study of SC Milatuzumab in SLE Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
8 The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus Unknown status NCT00797784 Phase 2 etanercept(Enbrel®)
9 Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Completed NCT00523588 Phase 2
10 Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2 KRP203 - 1.2mg;Placebo to KRP203 - 1.2 mg
11 To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2 CC-11050
12 Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE) Completed NCT00317681 Phase 2 Tacrolimus ointment
13 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Completed NCT01352988 Phase 2 Fumaric acid esters
14 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed NCT00708916 Phase 1, Phase 2 CC-10004
15 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Completed NCT02265744 Phase 2 BMS-931699;Placebo matching BMS-931699
16 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
17 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus Completed NCT02437890 Phase 2
18 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions Completed NCT01597050 Phase 2 R932333;Placebo
19 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions Completed NCT00625521 Phase 2 ASF 1096 0.5 % cream applied twice daily;Cream vehicle for ASF 1096 cream applied twice daily
20 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) Completed NCT00625157 Phase 2 ASF 1096 0.5 % cream;ASF 1096 placebo cream
21 A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus Completed NCT00001680 Phase 2 Thalidomide
22 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
23 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
24 Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Recruiting NCT03134222 Phase 2 Filgotinib;GS-9876;Filgotinib placebo;GS-9876 placebo
25 Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus Recruiting NCT03260166 Phase 2 nicotinamide
26 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Recruiting NCT02660944 Phase 2 RSLV-132;Placebo
27 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
28 Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus Recruiting NCT03451422 Phase 1, Phase 2 AMG 592;Placebo
29 An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus Recruiting NCT03252587 Phase 2 BMS-986165
30 A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE) Recruiting NCT02975336 Phase 2 Placebo;M2951;M2951;M2951;M2951
31 Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care Recruiting NCT03371251 Phase 1, Phase 2 BOS161721;Placebo
32 Study of Anti-Malarials in Incomplete Lupus Erythematosus Recruiting NCT03030118 Phase 2 Hydroxychloroquine;Placebo Oral Capsule
33 Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Active, not recruiting NCT02656082 Phase 2 Etanercept
34 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Terminated NCT01407679 Phase 2 Alitretinoin
35 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
36 TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment Terminated NCT02711813 Phase 2 TAB08
37 A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus Terminated NCT01466725 Phase 2 CC-930;Placebo
38 Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva Terminated NCT00308204 Phase 2 Raptiva (efalizumab)
39 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects Completed NCT02927457 Phase 1 GSK2646264 1%;Placebo
40 A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus Completed NCT01702740 Phase 1 1 mg/kg CNTO 136;4 mg/kg CNTO 136;10 mg/kg CNTO 136;Placebo
41 A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Recruiting NCT03817424 Phase 1 VIB7734;Placebo
42 A Study of NKTR-358 in Participants With Systemic Lupus Erythematosis (SLE) Recruiting NCT03556007 Phase 1 NKTR-358;Placebo
43 Autologous Polyclonal Tregs for Lupus Active, not recruiting NCT02428309 Phase 1
44 A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus Terminated NCT01470313 Phase 1 PD-0360324;Placebo
45 Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1 AMG 557;AMG 557 Placebo
46 Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus Terminated NCT01164917 Phase 1 AMG811;AMG811 Placebo
47 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Completed NCT01629784 Not Applicable
48 IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus Completed NCT01841619 Early Phase 1 IVIg
49 Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE) Completed NCT00633945 Not Applicable lenalidomide (Revlimid®)
50 Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) Completed NCT01146444 Not Applicable

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

41
Skin, Lung, Heart, Kidney, T Cells, Breast, Neutrophil

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 877)
# Title Authors Year
1
Canine Cutaneous Lupus Erythematosus: Newly Discovered Variants. ( 30227971 )
2019
2
Subacute cutaneous lupus erythematosus: is clopidogrel a trigger? ( 29327459 )
2018
3
CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study. ( 29728857 )
2018
4
Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. ( 29307217 )
2018
5
Cutaneous lupus erythematosus: clinico-pathologic correlation. ( 29368845 )
2018
6
Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. ( 29801110 )
2018
7
Drug-induced Subacute Cutaneous Lupus Erythematosus Caused by a Topical Beta Blocker - Timolol. ( 29782299 )
2018
8
Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report. ( 29625815 )
2018
9
Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study. ( 29496481 )
2018
10
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( 28989111 )
2018
11
Subacute cutaneous lupus erythematosus presenting in twins. ( 29436018 )
2018
12
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus. ( 29969701 )
2018
13
Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus. ( 29924416 )
2018
14
Incremental health care services and expenditures associated with depression among individuals with cutaneous lupus erythematosus (CLE). ( 29514557 )
2018
15
The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. ( 29631513 )
2018
16
Occupational subacute cutaneous lupus erythematosus caused by outdoor work. ( 29603599 )
2018
17
Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. ( 29349515 )
2018
18
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. ( 29061479 )
2018
19
Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus. ( 29924233 )
2018
20
Cutaneous lupus erythematosus in dogs: a comprehensive review. ( 29669547 )
2018
21
Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. ( 29760621 )
2018
22
Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. ( 29788808 )
2018
23
Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. ( 29885269 )
2018
24
Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. ( 29423919 )
2018
25
Chronic Cutaneous Lupus Erythematosus in a Blaschkoid Pattern over Face. ( 29692464 )
2018
26
Coexistence of chronic cutaneous lupus erythematosus and frontal fibrosing alopecia. ( 29723351 )
2018
27
Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent. ( 29570834 )
2018
28
Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern United States: The Georgia Lupus Registry. ( 29669194 )
2018
29
The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). ( 30521827 )
2018
30
Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus in a patient with progressive systemic sclerosis. ( 30028256 )
2018
31
Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists. ( 30033560 )
2018
32
Cutaneous lupus erythematosus: Reflecting on practice-changing observations over the past 50 years. ( 30047428 )
2018
33
Isoniazid-induced subacute cutaneous lupus erythematosus in an HIV-positive woman: a rare side effect to be aware of with the current expansion of isoniazid preventive therapy. ( 30061978 )
2018
34
Reply to: S2k guideline for treatment of cutaneous lupus erythematosus-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). ( 30098058 )
2018
35
Novel biological therapeutic approaches to cutaneous lupus erythematosus. ( 30118337 )
2018
36
Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients. ( 30133802 )
2018
37
Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus: report of a case and review of the literature. ( 30142736 )
2018
38
Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study. ( 30148164 )
2018
39
Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. ( 30167444 )
2018
40
Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study. ( 30175217 )
2018
41
Usefulness of Pulsed Dye Laser in Cutaneous Lupus Erythematosus. ( 30213381 )
2018
42
Drug-Induced Cutaneous Lupus Erythematosus: A Case Series of Five Patients with Bupropion-Associated Disease. ( 30222626 )
2018
43
Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. ( 30227141 )
2018
44
Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. ( 30243657 )
2018
45
Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death (PD)-1 therapy. ( 30244487 )
2018
46
Chronic cutaneous lupus erythematosus and topical clindamycin. ( 30249740 )
2018
47
Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. ( 30383114 )
2018
48
Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. ( 30394571 )
2018
49
Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. ( 30489484 )
2018
50
Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus. ( 30538816 )
2018

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

GO Terms for Cutaneous Lupus Erythematosus

Cellular components related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immunological synapse GO:0001772 8.62 GZMB ICAM1

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.78 CD70 CXCR3 IL18 TNF
2 leukocyte migration GO:0050900 9.67 ICAM1 SELE TNF
3 inflammatory response GO:0006954 9.56 CXCR3 IL18 SELE TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.54 ICAM1 IL18 TNF
5 leukocyte cell-cell adhesion GO:0007159 9.46 ICAM1 SELE
6 negative regulation of myoblast differentiation GO:0045662 9.43 IL18 TNF
7 natural killer cell mediated cytotoxicity GO:0042267 9.4 GZMB IL18
8 leukocyte tethering or rolling GO:0050901 9.32 SELE TNF
9 regulation of type I interferon production GO:0032479 9.16 TREX1 TRIM21
10 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 8.96 ICAM1 TNF
11 positive regulation of neuroinflammatory response GO:0150078 8.62 IL18 TNF

Molecular functions related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.62 CD70 TNF

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....